NCT07629583
To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 5 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 1 → 11 locations
- Start date changed from estimate of Oct 31, 2026 to Nov 2, 2026
- Notable Eligibility criteria expanded, about 20 words
- Study sites: 1 to 2
- Notable Recruitment opened
- Start date: Jul 31, 2026 to Oct 31, 2026
- Study sites: 0 to 1
- Study Status, Contacts/Locations, Referencesv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Percentage of Participants with Adverse Events (AEs)
Timeframe: Up to approximately 52 weeks
Secondary (7)
Serum Concentration of Cevostamab
Area Under the Concentration-Time Curve (AUC) of Cevostamab
Maximum Observed Serum Concentration (Cmax) of Cevostamab
Minimum Observed Serum Concentration (Cmin) of Cevostamab
Clearance (CL) of Cevostamab
Show 2 moreShow less
Volume of Distribution at Steady State (Vdss) of Cevostamab
Change from Baseline in the Presence Anti-Drug Antibodies (ADAs)
Arms and interventions
Dose Escalation and ExpansionExperimental
The study consists of a dose-escalation stage followed by an expansion stage. Participants in both stages will receive Cevostamab in a step-up dosing regimen, followed by a target dose.
Drugs: Cevostamab, Tocilizumab
Sites
11 sites in 6 countries
Brazil 4, China 3, Australia 1, France 1, Italy 1, Spain 1